EXEL News and Press, Exelixis Inc. From 11/02/23

2023-11-02 14:45:22 ET Summary Exelixis's Q3 earnings fell short of expectations, with lower-than-anticipated Earnings Per Share and total revenues. The company's pipeline includes innovative therapies and collaborations with partners to revolutionize cancer treatment. Despite...

2023-11-01 21:43:08 ET Exelixis (EXEL) Q3 2023 Earnings Conference Call November 1, 2023 5:00 PM ET Company Participants Susan Hubbard - Executive Vice President, Public Affairs and Investor Relations Mike Morrissey - President and Chief Executive Officer Chris S...

- Total Revenues of $471.9 million, Cabozantinib Franchise U.S. Net Product Revenues of $426.5 million - - Conference Call and Webcast Today at 5:00 PM Eastern Time - Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2023 and provi...

Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...

Exelixis Inc. (EXEL) is expected to report $0.12 for Q3 2023

2023-10-31 17:36:11 ET More on Exelixis Exelixis gains as Cabometyx patent trial ends Exelixis reports positive results for Cabometyx Exelixis started at Buy at Wainwright on targeted oncology pipeline For further details see: Exelixis Q3 2023 Earnings Pr...

2023-10-26 11:27:48 ET More on Exelixis Exelixis: Predominantly Single Molecule Cancer Franchise (Rating Downgrade) Exelixis: Positive Advanced Pancreatic/Extra-Pancreatic Neuroendocrine Tumor Data Brings 2 Big Catalysts On Deck Exelixis: Long-Term Problem Isn't Shar...

2023-10-25 08:30:32 ET Palm Beach, FL – October 25, 2023 – FinancialNewsMedia.com News Commentary – The R&D for cancer vaccines has been growing in the last few years and is projected to continue through the next decade. A cancer vaccine is used to eithe...

2023-10-23 13:17:24 ET More on Exelixis Exelixis: Predominantly Single Molecule Cancer Franchise (Rating Downgrade) Exelixis: Positive Advanced Pancreatic/Extra-Pancreatic Neuroendocrine Tumor Data Brings 2 Big Catalysts On Deck Exelixis: Long-Term Problem Isn't Shar...

2023-10-23 10:44:57 ET More on Exelixis Exelixis: Predominantly Single Molecule Cancer Franchise (Rating Downgrade) Exelixis: Positive Advanced Pancreatic/Extra-Pancreatic Neuroendocrine Tumor Data Brings 2 Big Catalysts On Deck Exelixis: Long-Term Problem Isn't Shar...